NEURACAP
M&A UpdateUpdated · 7 pages · Free to read

Managed Health Care M&A update, 14–28 September 2026

Bi-weekly update on the Managed Health Care sector covering share-price moves, company news and M&A activity for September 14–28, 2026. Built for investors, operators and advisors tracking managed care valuation, guidance updates and precedent deal benchmarks.

For information only. Not an appraisal or a fairness opinion.

The deeper read: Managed Health Care Sector Outlook — September 2026

Key figures

Sector median move
-11.3%
9 covered names, close-to-close
S&P 500 return
+0.8%
same two-week period
Alignment Healthcare (ALHC)
-38.7%
two-week window
M&A precedent EV/EBITDA median
10.5x
40 recorded deals

Read the report

NeuraCap

BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › MANAGED HEALTH CARE

Investors Reprice Risk Across Managed Care While the Market Holds Up

This update covers the sector's movers, company news and M&A activity for September 14–28, 2026.

September 14–28, 2026

Prepared by NeuraCap AI · Confidential

Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28

Managed Health Care Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice

1

1 / 7

Executive summary

All 9 covered Managed Health Care names fell over the two-week period, with a median move of -11.3% against a S&P 500 return of +0.8%, showing the pressure sat inside the sector rather than the broad market. Alignment Healthcare (ALHC) carried the steepest decline at -38.7% following shareholder securities investigations, while Astrana furnished updated FY2026 guidance mid-window. No new M&A transactions were recorded, leaving the 40-deal precedent set and its 10.5x EV/EBITDA median as the standing benchmark. Operating proof, not narrative, is what set the terms this period.

Key findings

  • All 9 covered names fell while the S&P 500 rose +0.8% over the same period
  • Alignment Healthcare's -38.7% move followed shareholder securities investigations
  • Astrana furnished updated FY2026 Adjusted EBITDA and revenue guidance mid-window
  • No new deals this period; 40 precedents still anchor the 10.5x EV/EBITDA median

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01
    BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE

    HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › MANAGED HEALTH CARE

    Cover slide introducing NeuraCap's bi-weekly Managed Health Care industry events and M&A update for September 14–28, 2026.

    We open this bi-weekly update with the Managed Health Care sector's events and M&A activity for September 14–28, 2026. Over the pages that follow we walk through what changed, who moved and why, what transacted, and what it means for your next decision. So what: this is the two-week read you need before your next planning conversation.

    Everything on this page

    BI-WEEKLY INDUSTRY EVENTS & M&A UPDATE HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › MANAGED HEALTH CARE Investors Reprice Risk Across Managed Care While the Market Holds Up This update covers the sector's movers, company news and M&A activity for September 14–28, 2026. September 14–28, 2026 Prepared by NeuraCap AI · Confidential Market data through 2026-09-28 · events and transactions from the two-week period 2026-09-14 → 2026-09-28 Managed Health Care Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    THE BI-WEEKLY BOTTOM LINE

    A Sector-Wide Drawdown Against a Market That Went the Other Way

    This slide summarizes the two-week period: all 9 covered names declined while the S&P 500 gained.

    Every one of the 9 names we track fell over this window, with a median move of -11.3%, even as the S&P 500 returned +0.8% over the same period. That gap tells us the pressure sat inside the sector rather than the broad market. We'll walk through the names that drove it and what the record shows about why. So what: this was a sector story, not a market story.

    Everything on this page

    THE BI-WEEKLY BOTTOM LINE A Sector-Wide Drawdown Against a Market That Went the Other Way The two-week period in one page · 9 covered names, close-to-close · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Driver attributions use calibrated language and are NeuraCap reads of the recorded evidence. Managed Health Care Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 2 1 9 of 9 Covered Names Fell; The Median Move Was -11.3% The S&P 500 returned +0.8% over the same two-week period. The pressure sat inside the sector rather than across the broad market, and it reached every covered name, not just the weakest. 2 Alignment Healthcare Carried the Period's Steepest Decline Alignment Healthcare, Inc. (ALHC) closed the window at -38.7%, with its worst single day of -19.9% on Sep 15. Two shareholder law firms announced securities investigations on Sep 14 and Sep 15. 3 Astrana Put Fresh Numbers on the Table Mid-Window Astrana Health, Inc. (ASTH) furnished an updated investor presentation on September 15 with FY2026 guidance of $3.8-$4.1 billion Adjusted EBITDA and $255-$280 million revenue, and Q2 2026 revenue of $938.2 million with $68.9 million of reported earnings detail. 4 The Standing View on What the Market Pays for Did Not Change NeuraCap's sector study carries a CY2027E P/E median of 19.4x, with the Premium tier at a 43.4x median and the Discount tier at 11.1x. This two-week period is consistent with that split: durability is still the thing being paid for. -2.0% Best mover — Nutex Health, Inc. (NUTX) worst: ALHC -38.7% · 0 up / 9 down of 9 covered -11.3% Sector median two-week return vs S&P 500 +0.8% 1 Company filings in the window 8-K events read for driver attribution

  3. 03
    PUBLIC MARKET MOVERS

    One Name Did the Damage, but the Whole Set Slid

    This slide ranks the two-week share price moves for covered names against a sector materiality bar.

    Alignment Healthcare's -38.7% move set the period's floor, with its worst single day at -19.9% on September 15. The sector median came in at -11.3%, measured against a sector-relative materiality bar of 16.9%, while the S&P 500 held at +0.8%. We link every move to the filings and headlines recorded in the window, so what follows is evidence, not speculation. So what: one name did the damage, but the pressure reached the whole set.

    Everything on this page

    PUBLIC MARKET MOVERS One Name Did the Damage, but the Whole Set Slid Bi-Weekly moves, close-to-close · September 14–28, 2026 · sector median -11.3% · S&P 500 +0.8% · materiality bar ±16.9% (sector-relative) Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Attribution links each move only to filings and headlines recorded in the window; where no driver is recorded, the page says so. Calibrated language throughout — NeuraCap reads, not asserted causation. Managed Health Care Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 3 Bi-Weekly return per company · teal above zero, amber below · sector median -11.3% Alignment Healthcare, Inc. (ALHC) -38.7% Shares moved following the securities investigations announced by Kaplan Fox on Sep 14 and Rosen Law Firm on Sep 15; the steepest single day, -19.9%, came on Sep 15. Disclosure and risk-adjustment scrutiny can reprice a Core-tier carrier faster than any single operating metric. COMPANY-SPECIFIC

  4. 04
    MAJOR NEWS & INDUSTRY CATALYSTS

    Access, Guidance and Community Work: What Companies Actually Did

    This slide lists the two-week period's highest-impact company events, each linked to its source filing or article.

    Astrana furnished an updated investor presentation on September 15, guiding FY2026 Adjusted EBITDA of $3.8-$4.1 billion and revenue of $255-$280 million, alongside Q2 2026 revenue of $938.2 million and $68.9 million of reported earnings detail. Each event on this page links back to its filing or article, so the read is traceable. So what: guidance updates like this move the debate from sentiment to disclosed numbers.

    Everything on this page

    MAJOR NEWS & INDUSTRY CATALYSTS Access, Guidance and Community Work: What Companies Actually Did The two-week period's highest-impact events · titles link to the underlying filing or article · September 14–28, 2026 Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. "Why it matters" lines are NeuraCap reads; each event links to its source. Sources are admitted in a fixed reliability order (SEC filings, press releases, established outlets); video and social platforms are never used. Managed Health Care Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 4 Sep 17 · NEWS · PRNewsWire Aetna, a CVS Health company, expanded bundled oncology prior authorizations across its Medicaid book Bundling authorizations for all eligible Medicaid members and all cancer types reduces friction with treating providers and speeds member access. Utilization management is being redesigned as a service standard, not just a cost gate. Sep 16 · NEWS · PRNewsWire CVS Health launched a national contest to put customer-designed art on its own-brand bandages A consumer-brand initiative from CVS Health Corp. (CVS) speaks to the retail side of an integrated model. Integrated payers keep working the consumer brand, not only the benefit design. Sep 16 · NEWS · Business Wire Molina funded an expansion of trauma-informed care for youth in Iowa Molina Healthcare, Inc. (MOH) is investing in the community footprint of a state Medicaid plan. Standing with the state and its provider base is part of how incumbency is defended through a procurement cycle. Medicaid incumbency is maintained in the state, not only in the bid document. Sep 15 · 8-K · SEC EDGAR Astrana Health furnished an updated investor presentation with FY2026 guidance and Q2 2026 results The filing puts FY2026 guidance of $3.8-$4.1 billion Adjusted EBITDA and $255-$280 million revenue alongside Q2 2026 revenue of $938.2 million. Care-delivery names are judged on forward cash earnings, not on the trailing period. Sep 17 · NEWS · Business Wire Humana published research linking pharmacy care coordination to better outcomes for cancer patients Humana Inc. (HUM) is building the evidence base for pharmacy integration inside a medical benefit. Pharmacy integration is being argued on outcomes as well as on unit cost. Sep 17 · NEWS · GlobeNewsWire A further law firm opened a securities fraud investigation into Alignment Healthcare A second and third firm joining the inquiry extends the legal overhang around Alignment Healthcare, Inc. (ALHC) into the back half of the window. Legal process, once opened, tends to stay on the page for several reporting periods.

  5. 05
    M&A & STRATEGIC ACTIVITY

    No New Transactions This Period; The Precedent Record Still Sets the Benchmark

    This slide reports that no new M&A transactions were recorded this period, with the precedent set at 40 deals and a 10.5x EV/EBITDA median.

    No new transactions entered the record this period, so the standing precedent set - 40 recorded deals at a 10.5x EV/LTM EBITDA median - remains the benchmark. We hold this line rather than re-presenting old deals as news. So what: the price of scale in this sector hasn't moved, and any new deal will be tested against that 10.5x median.

    Everything on this page

    M&A & STRATEGIC ACTIVITY No New Transactions This Period; The Precedent Record Still Sets the Benchmark September 14–28, 2026 · precedent transactions: 40 recorded deals · median 10.5x EV/LTM EBITDA Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. Deal multiples are LTM at announcement where disclosed; "why the deal happened" is a NeuraCap read of the recorded evidence. No old transactions are re-presented as news. Managed Health Care Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 5 No Material Transactions Announced No material sector transactions were announced during the period. The reference set still rests on 40 trailing precedent transactions carrying a median EV/EBITDA of 10.5x. A quiet two-week period is information: buyer appetite, financing conditions and seller expectations all read through a period with no new deals. The precedent transactions alongside still frame what buyers have paid. 40 Recorded precedent transactions the reference set buyers and sellers price against 10.5x Precedent median EV/LTM EBITDA LTM at announcement, where disclosed

  6. 06
    WHAT IT MEANS

    What This Two-Week Period Changes for You

    This slide translates the two-week period's evidence into implications for operators, acquirers and advisors.

    For owners and operators, this window rewarded operating proof - medical loss ratio against priced trend, expense discipline, and Star Ratings performance. For acquirers, the reference set is unchanged: no new deals against the 40-transaction precedent at a 10.5x median. For advisors, the theme is a sector-wide drawdown driven by company-level evidence rather than the broad market, which returned +0.8%. So what: operating proof, not narrative, is what sets the terms into the next plan year.

    Everything on this page

    WHAT IT MEANS What This Two-Week Period Changes for You The two-week period translated for the people who act on it · NeuraCap view · observations, not recommendations Source: NeuraCap analytics platform (universe, prices, filings, transaction records); publisher-sourced news where linked; market data through 2026-09-28. This page is analytical interpretation drawn from the two-week period's recorded evidence. It is not investment advice. Managed Health Care Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice Sources & methodology 6 Sector study 2026-09-28 P / E (CY2027E) median 19.4x 8 companies in the study 3 valuation tiers Standing thesis: Managed health care splits between scaled carriers and risk-bearing care delivery, with premiums spanning both FOR OWNERS & OPERATORS Operating Proof Is What the Period Rewarded The moves in this window tracked company-specific evidence more than anything else. The metrics that carried weight are the familiar ones: medical loss ratio against priced trend, administrative expense discipline, Star Ratings by contract FOR ACQUIRERS The Reference Set Is Unchanged This Period No new transactions entered the record over the two-week period, so the benchmark remains the 40 trailing precedents at a 10.5x median EV/EBITDA. FOR ADVISORS Lead with the Evidence the Period Produced The theme is a sector-wide drawdown driven by company-level evidence, not by the broad market, which returned +0.8%.

  7. 07
    SOURCES & METHODOLOGY

    Sources, Methodology and Important Notice

    This slide explains the sources and methodology behind the update and states the important notice.

    Every figure in this update links to the record it was taken from, and the publishers and filings drawn on for the period are listed on this page. This is how we keep the calibrated language honest - each read is tied to a document a reader can open. So what: you can verify every claim in this deck yourself.

    Everything on this page

    SOURCES & METHODOLOGY Sources, Methodology and Important Notice How this bi-weekly update is built and what each kind of statement rests on · September 14–28, 2026 · market data through 2026-09-28 Every figure in this update links to the record it was taken from; the publishers and filings drawn on for the period are listed above. Managed Health Care Bi-Weekly Update | September 14–28, 2026 | Confidential | Not investment advice 7 OBSERVED DATA Bi-Weekly stock moves are computed close-to-close over the stated window from the platform’s price series. Deal records, values and multiples come from the platform’s transaction record (SEC 8-K extractions) exactly as recorded; each figure links to its citation. Treasury rates come from the platform’s Treasury series and are shown only when the 10-year moved at least ten basis points over the window (it did not in this window, so no rate figures appear). UNIVERSE QUALITY The update universe is the platform’s approved company set for this sector, subject to a $100M market-cap floor so small, loosely related names cannot dominate the statistics. No covered name fell below the floor in this window. EVENTS & NEWS Company events are in-window 8-K filings; news items are publisher-sourced headlines fetched for the window (and any externally supplied items, marked as such). Operational and strategic developments (deals, partnerships, launches, expansion, guidance, leadership, regulatory outcomes) are shown first; capital-return mechanics and conference appearances are limited to one each. Every event links to its source. The deck never asserts an event that has no linked record. SOURCE HIERARCHY News is admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then transaction documents, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron’s and peers). Video and social platforms — including YouTube — are never used as sources. DRIVER ATTRIBUTION A stock move is linked to an event only when the event falls inside the window, and only in calibrated language ("the move appears to reflect…", "shares moved following…"). Where no driver is recorded, the page says so and compares the move to the sector median instead. ANALYTICAL INTERPRETATION "Why it matters", "why the deal happened" and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, and are labeled as such. INHERITED CONTEXT The standing sector view (thesis, valuation lens, sector median and tiering) is inherited from the NeuraCap sector study run_20260929T162023Z_530_prod (market data as of 2026-09-28) — distilled, never re-derived. That report’s own sources page governs its content; this update reads the period against it. IMPORTANT NOTICE This report is informational only. It is not investment advice, not a recommendation to buy or sell any security, and not an offer of any kind. Readers should perform their own diligence before acting on anything described here. Linked sources this two-week period: prnewswire.com · businesswire.com · sec.gov · globenewswire.com

Sources and methodology

This update covers Managed Health Care over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 9 listed companies whose core business is Managed Health Care under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Agilon Health, Inc. (AGL), Alignment Healthcare, Inc. (ALHC), Astrana Health, Inc. (ASTH), Clover Health Investments, Corp. (CLOV), Centene Corp. (CNC), CVS Health Corp. (CVS), Humana Inc. (HUM), Molina Healthcare, Inc. (MOH), Nutex Health, Inc. (NUTX). No covered name fell below the floor in this window.

Window and company universe

This update covers Managed Health Care over the 14-day window September 14–28, 2026; market data runs through September 28, 2026. The universe is the 9 listed companies whose core business is Managed Health Care under NeuraCap's industry classification, subject to a $100M market-capitalisation floor so that very small, loosely related names cannot dominate the movers and statistics. Companies covered: Agilon Health, Inc. (AGL), Alignment Healthcare, Inc. (ALHC), Astrana Health, Inc. (ASTH), Clover Health Investments, Corp. (CLOV), Centene Corp. (CNC), CVS Health Corp. (CVS), Humana Inc. (HUM), Molina Healthcare, Inc. (MOH), Nutex Health, Inc. (NUTX). No covered name fell below the floor in this window.

How the moves and statistics are computed

Each company's period move is the change in closing price from the last close before the window to the last close inside it (close-to-close). The sector median is the median of those moves across the covered names; the index return is computed the same way for the S&P 500 over the same dates. The largest single-day move inside the window is shown for each mover. Movers are the largest gainers and losers by period move; the attribution cards prefer movers whose in-window record explains the move. Movers carry the valuation tier assigned in the standing sector study (the latest NeuraCap sector outlook) where that study rated them.

Events, news and how a move is attributed

Company events are the 8-K filings made inside the window; news items are publisher-sourced headlines for the window, admitted in a fixed order of reliability: SEC filings first, then company press releases and investor-relations communications, then established outlets (Reuters, CNBC, The Wall Street Journal, Barron's and peers). Video and social platforms are never used. A move is linked to an event only when the event falls inside the window and only in calibrated language; where nothing in the record explains a move, the update says so rather than speculating. Every event links to its source.

Transactions in the window and the trailing record

Transactions are taken from SEC filings by announcement date; 0 were announced inside the window. The trailing record of 40 recorded transactions provides the reference multiples (EV over last-twelve-month revenue or EBITDA at announcement, as disclosed). A value whose own citation describes something other than the price paid is not shown as the deal value; transactions where the acquirer and the target are the same entity are treated as reorganisations and excluded.

Sources

Prices and index levels are market data through September 28, 2026; filings are the companies' SEC filings on EDGAR; press releases are the companies' own; other news items are from the established outlets named on each card; Treasury yields are published by the U.S. Department of the Treasury. Every figure and every event in the update links to its record.

Interpretation and important notice

'Why it matters', 'why the deal happened' and the what-it-means page are NeuraCap analytical views drawn from the recorded evidence, labelled as such. The update is informational: it is not investment advice, not a recommendation to buy or sell any security and not an offer of any kind.

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Managed Health Care?

Company valuation reports run the same method against a single business — public or private.